[The best in 2000 on thrombosis]

E Ferrari1

  • 1CHU de Nice, service de cardiologie, 30, avenue de la Vole-Romaine, 06002 Nice.

Archives Des Maladies Du Coeur Et Des Vaisseaux
|March 23, 2001
PubMed

Insights

New cardiology guidelines streamline chest pain evaluation, favoring shorter stays and subcutaneous low-molecular-weight heparin over continuous intravenous heparin for unstable angina. Risk stratification uses biomarkers for early intervention.

Area of Science:

  • Cardiology
  • Clinical Practice Guidelines
  • Emergency Medicine

Context:

  • Rapid advancements in cardiology necessitate updated clinical practice guidelines.
  • Chest pain units (CPUs) are evolving to manage suspected coronary artery disease more efficiently.
  • New data impacts the management of unstable angina and pulmonary embolism.

Purpose:

  • To summarize recent changes in cardiology practice, focusing on chest pain evaluation and treatment protocols.
  • To highlight the shift towards risk stratification using biomarkers and earlier invasive strategies.
  • To inform clinicians about updated management of unstable angina and pulmonary embolism.

Summary:

  • Over half of suspected coronary chest pain cases may only require a short stay in a chest pain unit, with discharge or outpatient referral guided by history, symptoms, Bayesian analysis, ECG, troponin, and clinical experience.
  • Unstable angina management is transitioning from continuous intravenous unfractionated heparin to subcutaneous low-molecular-weight heparin (LMWH), with continued use of anti-GPIIB-IIIA agents and early consideration for coronary angiography.
  • Risk stratification for coronary recurrence may utilize biological markers within hours of presentation. ST-elevation myocardial infarction protocols may involve half-dose thrombolysis with anti-GPIIB-IIIA. Pulmonary embolism diagnosis may involve d-dimer testing followed by scintigraphy or CT, with LMWH potentially replacing continuous heparin infusion.

Impact:

  • Implementation of these guidelines can lead to more efficient patient flow in chest pain units and reduced hospital stays.
  • Earlier risk stratification and intervention for unstable angina may improve patient outcomes.
  • Standardizing pulmonary embolism diagnosis and treatment with LMWH can enhance patient care and safety.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...